Upgrade to SI Premium - Free Trial

Form 8-K GeoVax Labs, Inc. For: Jun 17

June 17, 2026 4:33 PM
false 0000832489 0000832489 2026-06-17 2026-06-17
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
 

 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  June 17, 2026
 

 
GEOVAX LABS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-39563
 
87-0455038
(State or other jurisdiction of
incorporation or organization)
 
(Commission File No.)
 
(IRS Employee Identification No.)
 
1955 Lake Park Drive, Suite 300
SmyrnaGeorgia 30080
(Address of principal executive offices) (Zip code)
 
(678384-7220
(Registrants telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
GOVX
The Nasdaq Capital Market
 
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1

 
Item 5.07          Submission of Matters to a Vote of Security Holders.
 
The Company held its annual meeting of stockholders on June 17, 2026. The Company received proxies totaling 1,288,684 of its 2,892,570 issued and outstanding shares of common stock as of the record date of April 20, 2026. The stockholders voted on the following proposals and the results of the voting are presented below.
 
Election of Directors
 
Our stockholders voted to elect the slate of directors consisting of seven members to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified. There were a total of 810,066 broker non-votes on this item.
 
Nominee
For
Withheld
Randal D. Chase
420,305
58,313
David A. Dodd
418,963
59,655
Dean G. Kollintzas
420,198
58,420
Nicole Lemerond
417,920
61,426
Robert T. McNally
419,481
59,137
Jayne Morgan
420,422
58,196
John N. Spencer, Jr.
420,434
58,184
 
Approval of the February 2026 Warrant Exercise Proposal
 
Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 865,804 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the private placement offering which occurred on February 17, 2026. There were a total of 810,066 broker non-votes on this item.
 
For
Against
Abstain
395,198
65,103
18,317
 
Approval of the March 2026 Warrant Exercise Proposal
 
Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,269,316 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on March 31, 2026. There were a total of 810,066 broker non-votes on this item.
 
For
Against
Abstain
395,365
66,838
16,415
 
Approval of the May 2026 Warrant Exercise Proposal
 
Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,702,986 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on May 7, 2026. There were a total of 810,066 broker non-votes on this item.
 
For
Against
Abstain
375,831
35,336
67,451
 
Ratification of Independent Auditor
 
Our stockholders approved the ratification of Wipfli LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. There were no broker non-votes on this item.
 
For
Against
Abstain
1,185,525
37,409
65,750
 
2

Advisory Vote on the Compensation of our Named Executive Officers
 
Our stockholders approved, on an advisory basis, the compensation of our Named Executive Officers (as defined in the Proxy Statement). There were a total of 810,066 broker non-votes on this item.
 
For
Against
Abstain
385,843
65,826
26,949
 
Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers
 
Our stockholders approved, on an advisory basis, the frequency of future advisory votes on the compensation of our Named Executive Officers (as defined in the Proxy Statement). The determination was to hold such advisory votes on a three-year cycle.
 
1 Year
2 Years
3 Years
Abstain
339,064
24,463
97,058
18,033
 
3

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Date: June 17, 2026
 
 
GEOVAX LABS, INC.
 
 
 
 
By:
/s/ Mark W. Reynolds
 
 
Mark W. Reynolds
 
 
Chief Financial Officer
 
4

ATTACHMENTS / EXHIBITS

XBRL TAXONOMY EXTENSION SCHEMA

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

XBRL TAXONOMY EXTENSION LABEL LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: govx20260617_8k_htm.xml

Categories

SEC Filings